Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21194810 | 1.00 | HSD11B1 (0.42) | HSD11B1USP30EIF2AK4GRIN2BROCK2 | |
| SCHEMBL24009825 | 0.82 | USP2 (0.43) | HSD11B1EIF2AK4ROCK2 | |
| SCHEMBL21193004 | 0.82 | USP2 (0.43) | HSD11B1EIF2AK4ROCK2 | |
| SCHEMBL27150593 | 0.78 | HSD11B1 (0.57) | HSD11B1ROCK2 | |
| SCHEMBL27150592 | 0.78 | HSD11B1 (0.57) | HSD11B1ROCK2 | |
| SCHEMBL4730357 | 0.76 | USP30 (0.55) | USP30 | |
| SCHEMBL4730362 | 0.76 | USP30 (0.55) | USP30 | |
| SCHEMBL27166742 | 0.76 | EIF2AK4 (0.37) | HSD11B1EIF2AK4 | |
| SCHEMBL3790233 | 0.74 | USP30 (0.44) | USP30 | |
| SCHEMBL27875627 | 0.74 | USP30 (0.44) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-01-30 | — | — | US | disclosed |
| CN-115867284-A | Heterocyclic compounds as trigger receptor 2 agonists expressed on myeloid cells and methods of use | 安进公司 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11884675-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | HSD11B1 4315/4885USP30 4165/4885EIF2AK4 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.